Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-180-8 | CAS number: 92-70-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Limited scope of clinical/organ/tissue examinations and of functional observational battery; Apart from that, well documented and reported study, conducted according to OECD 407 test guideline of 1981 and in compliance with GLP.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 989
- Report date:
- 1989
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- of 1981
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 3-hydroxy-2-naphthoic acid
- EC Number:
- 202-180-8
- EC Name:
- 3-hydroxy-2-naphthoic acid
- Cas Number:
- 92-70-6
- Molecular formula:
- C11H8O3
- IUPAC Name:
- 3-hydroxynaphthalene-2-carboxylic acid
- Details on test material:
- - Name of test material (as cited in study report): BONS
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Hoechst AG breeding colony
- Age at study initiation: ca. 6 weeks
- Weight at study initiation (day -4): mean male: 101 g, female: 96 g
- Fasting period before study: none
- Housing: groups of 5, macrolon cages
- Diet (e.g. ad libitum): rat diet Altromin 1324, ad libitum
- Water (e.g. ad libitum): tap water, ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 +/-3
- Humidity (%): 50+/- 20
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: aqueous CMC (carboxymethyl cellulose)
- Details on oral exposure:
- The administration volume was 5 ml/kg bodyweight at all dose levels. Hence the concentration of test substance in the aqueous CMC preparation (vehicle) administered was 0.00, 0.24, 1.20 and 6.00 % (w/v) in the vehicle control, low dose, mid dose and high dose groups, respectively.
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 28 applications within 29 days
- Frequency of treatment:
- 7 days/week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 12, 60, 300 mg/kg bw/day (mf)
Basis:
actual ingested
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Positive control:
- Not applicable.
Examinations
- Observations and examinations performed and frequency:
- Clinical observations: twice daily.
Functional observations (not specified), and examination of eyes, oral cavity and teeth: at weekly intervals.
Body weights: determined at beginning of the study and then twice per week.
food consumption: determined twice per week.
water consumption: determined once per week.
Haematology/Clinical chemistry/Urinalysis: at study end from all animals. - Sacrifice and pathology:
- All animals were killed on day 29 after 28 consecutive days of oral (gavage) treatment.
Organ weights and organ to body weight ratios determined: heart, lung, liver, kidneys, spleen, testes, adrenals.
Organs/tissues examined at necropsy (macroscopic and microscopic): heart, lung, liver, kidneys, spleen, stomach, jejunum, colon, thymus, testes, adrenals, bone marrow. - Other examinations:
- No
- Statistics:
- Statistics: various methods (not specified), significance level p=0.05
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- water consumption increased at 300 mg/kg at day 7 and day 14
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Phosphate decreased , bilirubin increased at 300 mg/kg bw . Although values were within the range of historical controls they are considered to be substance related because of the distinct deviation from the concurrent control.
- Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- bilirubin (ca 35 µmol/L) in female at 300 mg/kg bw
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- on behaviour
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- slightly increased liver weight in females at 300 mg/kg bw
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- adrenal gland findings in females at 60 and 300 mg/kg bw.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- necrosis of adrenal cortex in one female at 60 mg/kg bw and in one female at 300 mg/kg bw
- Histopathological findings: neoplastic:
- not specified
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- 60 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: At 300 mg/kg/day decreased serum phosphate level (toxiccological relevance of this finding is unclear), increased bilirubin concentration in serum and urine but without microscopic correlates in the liver.
- Dose descriptor:
- NOEL
- Effect level:
- 12 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
The administration of the test substance had no influence on body weights, food consumption and behaviour of the animals. No mortality was observed. There were no neurological impairments, no eye opacities and no pathological findings in the oral cavity or teeth. 300 mg/kg bw: an increased water consumption was observed during the first two study weeks; at the end of the study, a significant decrease in serum phosphate, and an increase in serum bilirubin levels were observed when compared to the controls (the levels were within the normal range of the historical controls). In both sexes, bilirubin was found in the urine (ca. 35 µmol/L) and serum. Females showed a slight, but statistically significant increase in liver to bodyweight ratios (without histopathological correlate)(no further details available). At histopathology, one out of five females of the high-dose and one out of five female of the mid-dose group showed adrenal necroses. Examination of the animal from the intermediate dose group revealed diffuse necrosis of the right adrenal cortex. Complete necrosis of the adrenal cortex was detected in the female of the high dose group. Liver fibrosis, and changes in the lobular structure were microscopically seen in one of the females of the low-dose group, but considered as a chance event due to the lack of a dose-response.
Applicant's summary and conclusion
- Conclusions:
- For male animals the no-observed-effect-level (NOEL) was set at 60 mg/kg/day, because of decreased serum phosphate levels (toxicological relevance of this finding is unclear) and increased bilirubin concentration in serum and urine (but without microscopic correlates in the liver). For female animals the no-observed-effect-level (NOEL) was set at 12 mg/kg/day, mainly because of necroses of the adrenal cortex in one female each at 60 and 300 mg/kg/day. In addition, at 300 mg/kg decreased serum phosphate levels, increased bilirubin concentration in serum and urine and slightly increased liver to bodyweight ratios (but without histopathological correlates in the liver) were evident.
- Executive summary:
Rats (5 males and 5 females/dose group) were treated by oral gavage administration with 3-Hydroxy-2-naphthoic acid at dose levels of 0, 12, 60 or 300 mg/kg bodyweight/day once daily, seven days/week over 28 days. All animals were killed after 28 treatment days (day 29). At regular intervals during the study, eyes, oral cavities and teeth were examined and clinical signs, functional observations (not specified), body weights, food consumption and water consumption were recorded. In addition, at the end of the study, haematology, clinical chemistry and urinalysis examinations were performed on all animals. Organ weights were determined and macroscopic pathology and histopathology were performed on a number of organs/tissues from all animals.
Bodyweight, food consumption and animal behavior were unaffected by treatment with the test substance and mortality, neurological impairment, eye opacities and pathological findings in oral cavity or teeth were not evident at all dose levels. At 12 mg/kg/day, no signs of toxicity attributable to treatment with the test substance were evident. At 60 mg/kg/day, male animals were unaffected by treatment, whereas a relationship of necroses in the adrenal cortex in one female at 60 and one female at 300 mg/kg/day to treatment with the test item could not be entirely discounted. In addition, at 300 mg/kg/day a transient increase in water consumption, decreased serum phosphate levels and increased bilirubin concentrations in serum and urine were evident in both sexes and slightly increased liver to body weight ratios in females. Histopathological hepatic correlates were not evident.
The no-observed-effect-level (NOEL) was 60 mg/kg/day for male animals and 12 mg/kg/day for female animals.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.